H.C. Wainwright Raises Price Target on Atai Life Sciences to $15.
ByAinvest
Thursday, Jul 31, 2025 11:48 pm ET1min read
ATAI--
The firm highlighted BPL-003's compelling Phase 2b data in treatment-resistant depression, which showed statistically significant reductions in the MADRS depression scale as early as Day 2, with most patients becoming discharge-ready within 90 minutes. Based on these results, H.C. Wainwright increased its probability of success for BPL-003 to 85% from 60% previously, while removing RL-007 from its valuation model as Atai prepares to engage regulators in the third quarter of 2025 and initiate a Phase 3 trial in the first half of 2026.
Other analysts have also shown confidence in Atai's prospects. Canaccord Genuity raised its price target to $12, maintaining a Buy rating. Aegis Capital reiterated its Buy rating with an $8 price target. Oppenheimer initiated coverage of Atai with an Outperform rating and a $14 price target. These developments reflect a mix of challenges and opportunities for Atai Life Sciences as it navigates its clinical trials and market evaluations.
References:
[1] https://za.investing.com/news/analyst-ratings/hc-wainwright-raises-atai-life-sciences-stock-price-target-to-15-on-bpl003-potential-93CH-3813453
[2] https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-atai-life-sciences-stock-price-target-to-15-on-bpl003-potential-93CH-4162730
OPY--
H.C. Wainwright analyst Patrick Trucchio raised the price target on Atai Life Sciences (ATAI) to $15 from $10 while maintaining a Buy rating. Despite missing the primary endpoint in a Phase 2b trial, the firm is bullish on the company due to its focus on its wholly-owned psychedelics pipeline, including BPL-003, which has exceeded expectations.
H.C. Wainwright analyst Patrick Trucchio has raised the price target on Atai Life Sciences (ATAI) to $15 from $10, while maintaining a Buy rating on the stock. This comes after the biotech company's Phase 2b trial for inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia missed its primary endpoint. Despite this setback, the firm remains optimistic about Atai's future, particularly its wholly-owned psychedelics pipeline, including BPL-003.The firm highlighted BPL-003's compelling Phase 2b data in treatment-resistant depression, which showed statistically significant reductions in the MADRS depression scale as early as Day 2, with most patients becoming discharge-ready within 90 minutes. Based on these results, H.C. Wainwright increased its probability of success for BPL-003 to 85% from 60% previously, while removing RL-007 from its valuation model as Atai prepares to engage regulators in the third quarter of 2025 and initiate a Phase 3 trial in the first half of 2026.
Other analysts have also shown confidence in Atai's prospects. Canaccord Genuity raised its price target to $12, maintaining a Buy rating. Aegis Capital reiterated its Buy rating with an $8 price target. Oppenheimer initiated coverage of Atai with an Outperform rating and a $14 price target. These developments reflect a mix of challenges and opportunities for Atai Life Sciences as it navigates its clinical trials and market evaluations.
References:
[1] https://za.investing.com/news/analyst-ratings/hc-wainwright-raises-atai-life-sciences-stock-price-target-to-15-on-bpl003-potential-93CH-3813453
[2] https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-atai-life-sciences-stock-price-target-to-15-on-bpl003-potential-93CH-4162730
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet